
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Most parents are unaware of a FDA advisory recommending that OTC cough and cold medications should not be give to children aged younger than 2 years.






